Bowel Disease Group Will Use Illumina's BeadChip for IBD Study
The NIDDK Inflammatory Bowel Disease Genetics Consortium will use Illumina's Sentrix HumanHap300 BeadChips and Infinium assay reagents for a genome-wide study, Illumina said last week.
The consortium will genotype over 2,000 case-control samples to help identify genetic variants that increase susceptibility to Crohn's disease.
One thousand control individuals will be typed as part of the study, and the control genotypes will be made available to the scientific community.
The genotyping will be performed at the Feinstein Institute for Medical Research, part of the North Shore-Long Island Jewish Health System.
Genizon BioSciences Adopts Illumina's BeadChips for Disease-Association Research
Genizon BioSciences will use Illumina's whole-genome genotyping platform for its disease-association research program, Illumina said last week.
Genizon will conduct whole genome-association studies on at least 16,000 case and control samples in 11 common diseases over the next year and a half, Illumina said. Genizon has completed three such studies.
DNA samples will be collected in collaboration with over 900 clinical investigators in Quebec. Genizon will use a custom version of Illumina's Sentrix HumanHap300 BeadChip, tailored to genetic sharing in the Quebec population, to query over 350,000 SNP loci per sample.
Genizon will expand its existing Illumina system with six additional BeadArray Readers, extensive automation, LIMS to integrate workflows, and new BeadStudio software.
Cold Spring Biotech to Distribute CombiMatrix Products in China and Taiwan
Cold Spring Biotech will distribute CombiMatrix products and services in mainland China, Taiwan, and Hong Kong, Acacia Research said last week.
Under the non-exclusive distribution agreement, Cold Spring Biotech will market and sell CustomArrays and CatalogArrays, including the company's new Influenza A Research Microarray.
With eight offices in Taiwan and mainland China, Cold Spring Biotech opens a rapidly growing market to CombiMatrix, parent company Acacia Research said. CombiMatrix's Influenza A Research Microarrays will be used to test for Influenza H5N1.
US Gov't Awards CombiMatrix Additional $2.4M to Develop Microarrays for Biothreat Detection
Acacia Research said this week that its CombiMatrix group has been awarded $2.4 million from the US Department of Defense to further develop microarrays for detecting biological and chemical threat agents.
CombiMatrix was originally awarded $5.9 million by the DoD in March 2004 to develop its microarray technology for biothreat detection (see BAN 3/10/2004). The company said it is also in the midst of an additional $2.1 million contract from DoD.
Under the original contract, CombiMatrix was to develop an automated system for detecting biothreats such as Bacillus anthracis, Yersinia pestis, and toxins.